Abstract | BACKGROUND: METHODS: We conducted a systematic review of studies reporting on the efficacy and safety of clofazimine as part of combination therapy for DR-TB. Six databases and six conference abstract sites were searched from inception until April 2012. All studies involving the use of clofazimine in the treatment of DR-TB were included. RESULTS: Twelve studies, comprising 3489 patients across 10 countries, were included in this review. Treatment success ranged from 16.5% (95% CI 2.7%-38.7%) to 87.8% (95% CI 76.8%-95.6%), with an overall pooled proportion of 61.96% achieving treatment success (95% CI 52.79%-71.12%) (τ(2) 0.07). Mortality, treatment interruptions, defaulting and adverse events were all in line with DR-TB treatment outcomes overall. The most commonly reported adverse events were gastrointestinal disturbances and skin pigmentation. CONCLUSIONS: The available evidence to date suggests that clofazimine could be considered as an additional therapeutic option in the treatment of DR-TB. The optimal dose of clofazimine and duration of use require further investigation.
|
Authors | Teesta Dey, Grania Brigden, Helen Cox, Zara Shubber, Graham Cooke, Nathan Ford |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 68
Issue 2
Pg. 284-93
(Feb 2013)
ISSN: 1460-2091 [Electronic] England |
PMID | 23054996
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Chemical References |
- Antitubercular Agents
- Clofazimine
|
Topics |
- Antitubercular Agents
(adverse effects, therapeutic use)
- Clofazimine
(adverse effects, therapeutic use)
- Drug Therapy, Combination
(adverse effects, methods)
- Humans
- Treatment Outcome
- Tuberculosis, Multidrug-Resistant
(drug therapy)
|